{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T01:16:02Z","timestamp":1772846162798,"version":"3.50.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["2130\/19"],"award-info":[{"award-number":["2130\/19"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Duchenne muscular dystrophy (DMD) is a genetic disease caused by a mutation in the X-linked Dytrophin gene preventing the expression of the functional protein. Exon skipping therapy using antisense oligonucleotides (AONs) is a promising therapeutic strategy for DMD. While benefits of AON therapy have been demonstrated, some challenges remain before this strategy can be applied more comprehensively to DMD patients. These include instability of AONs due to low nuclease resistance and poor tissue uptake. Delivery systems have been examined to improve the availability and stability of oligonucleotide drugs, including polymeric carriers. Previously, we showed the potential of a hydrogel-based polymeric carrier in the form of injectable PEG-fibrinogen (PF) microspheres for delivery of chemically modified 2\u2032-O-methyl phosphorothioate (2OMePs) AONs. The PF microspheres proved to be cytocompatible and provided sustained release of the AONs for several weeks, causing increased cellular uptake in mdx dystrophic mouse cells. Here, we further investigated this delivery strategy by examining in vivo efficacy of this approach. The 2OMePS\/PEI polyplexes loaded in PF microspheres were delivered by intramuscular (IM) or intra-femoral (IF) injections. We examined the carrier biodegradation profiles, AON uptake efficiency, dystrophin restoration, and muscle histopathology. Both administration routes enhanced dystrophin restoration and improved the histopathology of the <jats:italic>mdx<\/jats:italic> mice muscles. The IF administration of the microspheres improved the efficacy of the 2OMePS AONs over the IM administration. This was demonstrated by a higher exon skipping percentage and a smaller percentage of centered nucleus fibers (CNF) found in H&amp;E-stained muscles. The restoration of dystrophin expression found for both IM and IF treatments revealed a reduced dystrophic phenotype of the treated muscles. The study concludes that injectable PF microspheres can be used as a carrier system to improve the overall therapeutic outcomes of exon skipping-based therapy for treating DMD.<\/jats:p>","DOI":"10.1038\/s41419-022-05166-0","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T05:03:08Z","timestamp":1662699788000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["In vivo restoration of dystrophin expression in mdx mice using intra-muscular and intra-arterial injections of hydrogel microsphere carriers of exon skipping antisense oligonucleotides"],"prefix":"10.1038","volume":"13","author":[{"given":"Shani Attias","family":"Cohen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orit","family":"Bar-Am","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Fuoco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galit","family":"Saar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1742-3969","authenticated-orcid":false,"given":"Cesare","family":"Gargioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6964-8567","authenticated-orcid":false,"given":"Dror","family":"Seliktar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,9]]},"reference":[{"key":"5166_CR1","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/mus.24880","volume":"53","author":"J Chung","year":"2016","unstructured":"Chung J, Smith AL, Hughes SC, Niizawa G, Abdel-Hamid HZ, Naylor EW, et al. Twenty-year follow-up of newborn screening for patients with muscular dystrophy. Muscle Nerve. 2016;53:570\u20138.","journal-title":"Muscle Nerve"},{"key":"5166_CR2","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1002\/cphy.c140048","volume":"5","author":"QQ Gao","year":"2015","unstructured":"Gao QQ, McNally EM. The dystrophin complex: structure, function, and implications for therapy. Compr Physiol. 2015;5:1223\u201339.","journal-title":"Compr Physiol"},{"key":"5166_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S1474-4422(09)70272-8","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2010;9:177\u201389.","journal-title":"Lancet Neurol"},{"key":"5166_CR4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1126\/science.aad5143","volume":"351","author":"CE Nelson","year":"2016","unstructured":"Nelson CE, Hakim CH, Ousterout DG, Thakore PI, Moreb EA, Rivera RMC, et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science (80-). 2016;351:403\u20137.","journal-title":"Science (80-)"},{"key":"5166_CR5","doi-asserted-by":"publisher","unstructured":"Amoasii L, Hildyard JCW, Li H, Sanchez-Ortiz E, Mireault A, Caballero D. et al. Gene editing restores dystrophin expression in a canine model of duchenne muscular dystrophy. Science (80-) 2018. https:\/\/doi.org\/10.1126\/aau1549(2018).","DOI":"10.1126\/aau1549(2018)"},{"key":"5166_CR6","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.molcel.2018.09.002","volume":"72","author":"J Yuan","year":"2018","unstructured":"Yuan J, Ma Y, Huang T, Chen Y, Peng Y, Li B, et al. Genetic modulation of RNA splicing with a CRISPR-guided cytidine deaminase. Mol Cell. 2018;72:380\u201394.e7.","journal-title":"Mol Cell"},{"key":"5166_CR7","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41434-020-0156-6","volume":"27","author":"K Dzierlega","year":"2020","unstructured":"Dzierlega K, Yokota T. Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy. Gene Ther. 2020;27:407\u201316.","journal-title":"Gene Ther"},{"key":"5166_CR8","doi-asserted-by":"publisher","unstructured":"Aoki Y, Yokota T, Nagata T, Nakamura A, Tanihata J, Saito T, et al. Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. https:\/\/doi.org\/10.1073\/pnas.1204638109.","DOI":"10.1073\/pnas.1204638109"},{"key":"5166_CR9","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/hmg\/10.15.1547","volume":"10","author":"JC van Deutekom","year":"2001","unstructured":"van Deutekom JC, Bremmer-Bout M, Janson AA, Ginjaar IB, Baas F, den Dunnen JT, et al. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet. 2001;10:1547\u201354.","journal-title":"Hum Mol Genet"},{"key":"5166_CR10","doi-asserted-by":"crossref","unstructured":"Lu-Nguyen N, Dickson G, Malerba A. Systemic intravenous administration of antisense therapeutics for combinatorial dystrophin and myostatin exon splice modulation. In: Methods in Molecular Biology. 2018, pp 343\u201354.","DOI":"10.1007\/978-1-4939-8651-4_21"},{"key":"5166_CR11","doi-asserted-by":"publisher","unstructured":"Verheul RC, Van Deutekom JCT, Datson NA. Digital droplet PCR for the absolute quantification of exon skipping induced by antisense oligonucleotides in (Pre-)clinical development for duchenne muscular dystrophy. PLoS ONE 2016; 11. https:\/\/doi.org\/10.1371\/journal.pone.0162467.","DOI":"10.1371\/journal.pone.0162467"},{"key":"5166_CR12","first-page":"347","volume":"1","author":"N Dias","year":"2002","unstructured":"Dias N, Stein CA. Minireview antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther. 2002;1:347\u201355.","journal-title":"Mol Cancer Ther"},{"key":"5166_CR13","doi-asserted-by":"publisher","unstructured":"Han G, Gu B, Cao L, Gao X, Wang Q, Seow Y, et al. ARTICLE Hexose enhances oligonucleotide delivery and exon skipping in dystrophin-deficient mdx mice. 2016. https:\/\/doi.org\/10.1038\/ncomms10981.","DOI":"10.1038\/ncomms10981"},{"key":"5166_CR14","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.omtn.2018.06.005","volume":"12","author":"G Han","year":"2018","unstructured":"Han G, Lin C, Ning H, Gao X, Yin HF. Long-term morpholino oligomers in hexose elicits long-lasting therapeutic improvements in mdx mice. Mol Ther - Nucleic Acids. 2018;12:478\u201389.","journal-title":"Mol Ther - Nucleic Acids"},{"key":"5166_CR15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.omtn.2016.11.009","volume":"6","author":"N Lu-Nguyen","year":"2017","unstructured":"Lu-Nguyen N, Malerba A, Popplewell L, Schnell F, Hanson G, Dickson G. Systemic antisense therapeutics for dystrophin and myostatin exon splice modulation improve muscle pathology of adult mdx mice. Mol Ther - Nucleic Acids. 2017;6:15\u201328.","journal-title":"Mol Ther - Nucleic Acids"},{"key":"5166_CR16","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1011367","volume":"364","author":"NM Goemans","year":"2011","unstructured":"Goemans NM, Tulinius M, van den Akker JT, Burm BE, Ekhart PF, Heuvelmans N, et al. Systemic administration of PRO051 in duchenne\u2019s muscular dystrophy. N. Engl J Med. 2011;364:1513\u201322.","journal-title":"N. Engl J Med"},{"key":"5166_CR17","first-page":"2471","volume":"8","author":"Y Shimizu-Motohashi","year":"2016","unstructured":"Shimizu-Motohashi Y, Miyatake S, Komaki H, Takeda S, Aoki Y. Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: From discovery to clinical trials. Am J Transl Res. 2016;8:2471\u201389.","journal-title":"Am J Transl Res."},{"key":"5166_CR18","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.ymthe.2017.03.023","volume":"25","author":"CA Stein","year":"2017","unstructured":"Stein CA, Castanotto D. FDA-approved oligonucleotide therapies in 2017. Mol Ther 2017;25:1069\u201375.","journal-title":"Mol Ther"},{"key":"5166_CR19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.nmd.2016.11.013","volume":"27","author":"N Goemans","year":"2017","unstructured":"Goemans N, Tulinius M, Kroksmark AK, Wilson R, van den Hauwe M, Campion G. Comparison of ambulatory capacity and disease progression of Duchenne muscular dystrophy subjects enrolled in the drisapersen DMD114673 study with a matched natural history cohort of subjects on daily corticosteroids. Neuromuscul Disord. 2017;27:203\u201313.","journal-title":"Neuromuscul Disord"},{"key":"5166_CR20","first-page":"234","volume":"11","author":"CH Evans","year":"2015","unstructured":"Evans CH, Huard J. Gene therapy approaches to regenerating the musculoskeletal system. Nat Publ Gr. 2015;11:234\u201342.","journal-title":"Nat Publ Gr"},{"key":"5166_CR21","doi-asserted-by":"publisher","unstructured":"Carballo-Pedrares N, Fuentes-Boquete I, D\u00edaz-Prado S, Rey-Rico A. Pharmaceutics Hydrogel-Based Localized Nonviral Gene Delivery in Regenerative Medicine Approaches-An Overview. 2020. https:\/\/doi.org\/10.3390\/pharmaceutics12080752.","DOI":"10.3390\/pharmaceutics12080752"},{"key":"5166_CR22","doi-asserted-by":"publisher","first-page":"9106","DOI":"10.1016\/j.biomaterials.2010.08.016","volume":"31","author":"Y Lei","year":"2010","unstructured":"Lei Y, Huang S, Sharif-Kashani P, Chen Y, Kavehpour P, Segura T. Incorporation of active DNA\/cationic polymer polyplexes into hydrogel scaffolds. Biomaterials. 2010;31:9106\u201316.","journal-title":"Biomaterials"},{"key":"5166_CR23","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jconrel.2011.01.028","volume":"153","author":"Y Lei","year":"2011","unstructured":"Lei Y, Rahim M, Ng Q, Segura T. Hyaluronic acid and fibrin hydrogels with concentrated DNA\/PEI polyplexes for local gene delivery. J Control Release. 2011;153:255\u201361.","journal-title":"J Control Release"},{"key":"5166_CR24","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0142-9612(03)00467-8","volume":"25","author":"YH Yun","year":"2004","unstructured":"Yun YH, Goetz DJ, Yellen P, Chen W. Hyaluronan microspheres for sustained gene delivery and site-specific targeting. Biomaterials. 2004;25:147\u201357.","journal-title":"Biomaterials"},{"key":"5166_CR25","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1016\/j.actbio.2012.07.014","volume":"8","author":"T Tokatlian","year":"2012","unstructured":"Tokatlian T, Cam C, Siegman SN, Lei Y, Segura T. Design and characterization of microporous hyaluronic acid hydrogels for in vitro gene transfer to mMSCs. Acta Biomater. 2012;8:3921\u201331.","journal-title":"Acta Biomater"},{"key":"5166_CR26","doi-asserted-by":"publisher","unstructured":"Kong HJ, Kim ES, Huang Y-C, Mooney DJ. Design of biodegradable hydrogel for the local and sustained delivery of angiogenic plasmid DNA. https:\/\/doi.org\/10.1007\/s11095-007-9526-7.","DOI":"10.1007\/s11095-007-9526-7"},{"key":"5166_CR27","doi-asserted-by":"publisher","unstructured":"Alam P, Haile B, Arif M, Pandey R, Rokvic M, Nieman M, et al. Inhibition of senescence-associated genes Rb1 and Meis2 in adult cardiomyocytes results in cell cycle reentry and cardiac repair post\u2013myocardial infarction. J Am Heart Assoc. 2019; 8. https:\/\/doi.org\/10.1161\/JAHA.119.012089.","DOI":"10.1161\/JAHA.119.012089"},{"key":"5166_CR28","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.1016\/j.actbio.2014.05.011","volume":"10","author":"CJ Needham","year":"2014","unstructured":"Needham CJ, Shah SR, Dahlin RL, Kinard LA, Lam J, Watson BM, et al. Osteochondral tissue regeneration through polymeric delivery of DNA encoding for the SOX trio and RUNX2. Acta Biomater. 2014;10:4103\u201312.","journal-title":"Acta Biomater"},{"key":"5166_CR29","doi-asserted-by":"publisher","first-page":"6533","DOI":"10.1016\/j.biomaterials.2012.05.043","volume":"33","author":"Y Li","year":"2012","unstructured":"Li Y, Yang C, Khan M, Liu S, Hedrick JL, Yang YY, et al. Nanostructured PEG-based hydrogels with tunable physical properties for gene delivery to human mesenchymal stem cells. Biomaterials. 2012;33:6533\u201341.","journal-title":"Biomaterials"},{"key":"5166_CR30","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1016\/j.biomaterials.2004.07.055","volume":"26","author":"KW Chun","year":"2005","unstructured":"Chun KW, Lee JB, Kim SH, Park TG. Controlled release of plasmid DNA from photo-cross-linked pluronic hydrogels. Biomaterials. 2005;26:3319\u201326.","journal-title":"Biomaterials"},{"key":"5166_CR31","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S0065-2660(05)53009-8","volume":"53","author":"A Kabanov","year":"2005","unstructured":"Kabanov A, Zhu J, Alakhov V. Pluronic block copolymers for gene delivery. Adv Genet. 2005;53:231\u201361.","journal-title":"Adv Genet"},{"key":"5166_CR32","doi-asserted-by":"publisher","first-page":"111038","DOI":"10.1016\/j.eurpolymj.2022.111038","volume":"166","author":"SA Cohen","year":"2022","unstructured":"Cohen SA, Simaan-Yameen H, Fuoco C, Gargioli C, Seliktar D. Injectable hydrogel microspheres for sustained gene delivery of antisense oligonucleotides to restore the expression of dystrophin protein in duchenne muscular dystrophy. Eur Polym J. 2022;166:111038.","journal-title":"Eur Polym J"},{"key":"5166_CR33","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/sita.200500073","volume":"6","author":"C Ehrhardt","year":"2006","unstructured":"Ehrhardt C, Schmolke M, Matzke A, Knoblauch A, Will C, Wixler V, et al. Polyethylenimine, a cost-effective transfection reagent. Signal Transduct. 2006;6:179\u201384.","journal-title":"Signal Transduct"},{"key":"5166_CR34","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1089\/oli.2010.0271","volume":"21","author":"YT Ko","year":"2011","unstructured":"Ko YT, Bickel U, Huang J. Polyethylenimine\/oligonucleotide polyplexes investigated by fluorescence resonance energy transfer and fluorescence anisotropy. Oligonucleotides. 2011;21:109\u201314.","journal-title":"Oligonucleotides"},{"key":"5166_CR35","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ejpb.2004.11.011","volume":"60","author":"U Lungwitz","year":"2005","unstructured":"Lungwitz U, Breunig M, Blunk T, G\u00f6pferich A. Polyethylenimine-based non-viral gene delivery systems. Eur J Pharm Biopharm. 2005;60:247\u201366.","journal-title":"Eur J Pharm Biopharm"},{"key":"5166_CR36","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.biomaterials.2016.10.052","volume":"115","author":"S Pradhan","year":"2017","unstructured":"Pradhan S, Clary JM, Seliktar D, Lipke EA. A three-dimensional spheroidal cancer model based on PEG-fibrinogen hydrogel microspheres. Biomaterials. 2017;115:141\u201354.","journal-title":"Biomaterials"},{"key":"5166_CR37","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1016\/j.actbio.2011.06.011","volume":"7","author":"CL Franco","year":"2011","unstructured":"Franco CL, Price J, West JL. Development and optimization of a dual-photoinitiator, emulsion-based technique for rapid generation of cell-laden hydrogel microspheres. Acta Biomater. 2011;7:3267\u201376.","journal-title":"Acta Biomater"},{"key":"5166_CR38","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/jgm.716","volume":"7","author":"P Gonin","year":"2005","unstructured":"Gonin P, Arandel L, Van Wittenberghe L, Marais T, Perez N, Danos O. Femoral intra-arterial injection: a tool to deliver and assess recombinant AAV constructs in rodents whole hind limb. J Gene Med. 2005;7:782\u201391.","journal-title":"J Gene Med"},{"key":"5166_CR39","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/7439","volume":"5","author":"JP Greelish","year":"1999","unstructured":"Greelish JP, Su LT, Lankford EB, Burkman JM, Chen H, Konig SK, et al. Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector. Nat Med. 1999;5:439\u201343.","journal-title":"Nat Med"},{"key":"5166_CR40","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/jgm.838","volume":"8","author":"S Fletcher","year":"2006","unstructured":"Fletcher S, Honeyman K, Fall AM, Harding PL, Johnsen RD, Wilton SD. Dystrophin expression in themdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide. J Gene Med. 2006;8:207\u201316.","journal-title":"J Gene Med"},{"key":"5166_CR41","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1073\/pnas.0406700102","volume":"102","author":"QL Lu","year":"2005","unstructured":"Lu QL, Rabinowitz A, Chen YC, Yokota T, Yin H, Alter J, et al. Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA. 2005;102:198\u2013203.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5166_CR42","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/sj.gt.3301874","volume":"10","author":"QL Lu","year":"2003","unstructured":"Lu QL, Bou-Gharios G, Partridge TA. Non-viral gene delivery in skeletal muscle: a protein factory. Gene Ther. 2003;10:131\u201342.","journal-title":"Gene Ther"},{"key":"5166_CR43","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1126\/science.1082254","volume":"301","author":"M Sampaolesi","year":"2003","unstructured":"Sampaolesi M, Torrente Y, Innocenzi A, Tonlorenzi R, D\u2019Antona G, Pellegrino MA, et al. Cell therapy of \u03b1-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. Science (80-). 2003;301:487\u201392.","journal-title":"Science (80-)"},{"key":"5166_CR44","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nm.1852","volume":"14","author":"C Gargioli","year":"2008","unstructured":"Gargioli C, Coletta M, De Grandis F, Cannata SM, Cossu G. PlGF-MMP-9-expressing cells restore microcirculation and efficacy of cell therapy in aged dystrophic muscle. Nat Med. 2008;14:973\u20138.","journal-title":"Nat Med"},{"key":"5166_CR45","doi-asserted-by":"publisher","first-page":"7297","DOI":"10.1073\/pnas.92.16.7297","volume":"92","author":"O Boussif","year":"1995","unstructured":"Boussif O, Lezoualc\u2019h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA. 1995;92:7297\u2013301.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5166_CR46","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/j.biomaterials.2005.09.038","volume":"27","author":"D Dikovsky","year":"2006","unstructured":"Dikovsky D, Bianco-Peled H, Seliktar D. The effect of structural alterations of PEG-fibrinogen hydrogel scaffolds on 3-D cellular morphology and cellular migration. Biomaterials. 2006;27:1496\u2013506.","journal-title":"Biomaterials"},{"key":"5166_CR47","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.scr.2014.10.007","volume":"14","author":"L Boldrin","year":"2015","unstructured":"Boldrin L, Zammit PS, Morgan JE. Satellite cells from dystrophic muscle retain regenerative capacity. Stem Cell Res. 2015;14:20\u201329.","journal-title":"Stem Cell Res"},{"key":"5166_CR48","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1634\/stemcells.2005-0547","volume":"24","author":"R Sarig","year":"2006","unstructured":"Sarig R, Baruchi Z, Fuchs O, Nudel U, Yaffe D. Regeneration and transdifferentiation potential of muscle-derived stem cells propagated as myospheres. Stem Cells. 2006;24:1769\u201378.","journal-title":"Stem Cells"},{"key":"5166_CR49","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1073\/pnas.1502232112","volume":"112","author":"A Berdichevski","year":"2015","unstructured":"Berdichevski A, Yameen HS, Dafni H, Neeman M, Seliktar D. Using bimodal MRI\/fluorescence imaging to identify host angiogenic response to implants. Proc Natl Acad Sci USA. 2015;112:5147\u201352.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5166_CR50","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/jbm.a.35899","volume":"105","author":"S Pradhan","year":"2017","unstructured":"Pradhan S, Hassani I, Seeto WJ, Lipke EA. PEG-fibrinogen hydrogels for three-dimensional breast cancer cell culture. J Biomed Mater Res - Part A. 2017;105:236\u201352.","journal-title":"J Biomed Mater Res - Part A"},{"key":"5166_CR51","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/jgm.696","volume":"7","author":"A Akinc","year":"2005","unstructured":"Akinc A, Thomas M, Klibanov AM, Langer R. Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. J Gene Med. 2005;7:657\u201363.","journal-title":"J Gene Med"},{"key":"5166_CR52","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.biomaterials.2008.09.027","volume":"30","author":"Y Lei","year":"2009","unstructured":"Lei Y, Segura T. DNA delivery from matrix metalloproteinase degradable poly(ethylene glycol) hydrogels to mouse cloned mesenchymal stem cells. Biomaterials. 2009;30:254\u201365.","journal-title":"Biomaterials"},{"key":"5166_CR53","doi-asserted-by":"publisher","unstructured":"Frisman I, Seliktar D, Bianco-Peled H. Nanostructuring PEG-fibrinogen hydrogels to control cellular morphogenesis. Biomaterials 2011. https:\/\/doi.org\/10.1016\/j.biomaterials.2011.06.078.","DOI":"10.1016\/j.biomaterials.2011.06.078"},{"key":"5166_CR54","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.1111\/febs.12267","volume":"280","author":"TA Partridge","year":"2013","unstructured":"Partridge TA. The mdx mouse model as a surrogate for Duchenne muscular dystrophy. FEBS J. 2013;280:4177\u201386.","journal-title":"FEBS J"},{"key":"5166_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.aca.2012.12.007","volume":"764","author":"L Telgmann","year":"2013","unstructured":"Telgmann L, Sperling M, Karst U. Determination of gadolinium-based MRI contrast agents in biological and environmental samples: a review. Anal Chim Acta. 2013;764:1\u201316.","journal-title":"Anal Chim Acta"},{"key":"5166_CR56","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nm.3765","volume":"21","author":"A Goyenvalle","year":"2015","unstructured":"Goyenvalle A, Griffith G, Babbs A, Andaloussi SEL, Ezzat K, Avril A, et al. Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers. Nat Med. 2015;21:270\u20135.","journal-title":"Nat Med"},{"key":"5166_CR57","doi-asserted-by":"publisher","unstructured":"Novak JS, Hogarth MW, Boehler JF, Nearing M, Vila MC, Heredia R, et al. Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle. https:\/\/doi.org\/10.1038\/s41467-017-00924-7.","DOI":"10.1038\/s41467-017-00924-7"},{"key":"5166_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40478-020-01106-1","volume":"9","author":"D Scaglioni","year":"2021","unstructured":"Scaglioni D, Catapano F, Ellis M, Torelli S, Chambers D, Feng L, et al. The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy. Acta Neuropathol Commun. 2021;9:1\u201317.","journal-title":"Acta Neuropathol Commun"},{"key":"5166_CR59","doi-asserted-by":"publisher","first-page":"477","DOI":"10.7150\/thno.10823","volume":"5","author":"D-H Kim","year":"2015","unstructured":"Kim D-H, Chen J, Omary RA, Larson AC. MRI visible drug eluting magnetic microspheres for transcatheter intra-arterial delivery to liver tumors. Theranostics. 2015;5:477\u201388.","journal-title":"Theranostics"},{"key":"5166_CR60","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1158\/1078-0432.CCR-05-2225","volume":"12","author":"K Hong","year":"2006","unstructured":"Hong K, Khwaja A, Liapi E, Torbenson MS, Georgiades CS, Geschwind J-FH. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res. 2006;12:2563\u20137.","journal-title":"Clin Cancer Res"},{"key":"5166_CR61","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jps.2600780303","volume":"78","author":"JM Gallo","year":"1989","unstructured":"Gallo JM, Gupta PK, Hung CT, Perrier DG. Evaluation of drug delivery following the administration of magnetic albumin microspheres containing adriamycin to the rat. J Pharm Sci. 1989;78:190\u20134.","journal-title":"J Pharm Sci"},{"key":"5166_CR62","doi-asserted-by":"publisher","first-page":"31937","DOI":"10.1371\/journal.pone.0031937","volume":"7","author":"M Van Putten","year":"2012","unstructured":"Van Putten M, Hulsker M, Nadarajah VD, Van Heiningen SH, Van, Huizen E. The effects of low levels of dystrophin on mouse muscle function and pathology. PLoS ONE. 2012;7:31937.","journal-title":"PLoS ONE"},{"key":"5166_CR63","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1242\/dmm.018424","volume":"8","author":"JW McGreevy","year":"2015","unstructured":"McGreevy JW, Hakim CH, McIntosh MA, Duan D. Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy. DMM Dis Model Mech. 2015;8:195\u2013213.","journal-title":"DMM Dis Model Mech."},{"key":"5166_CR64","doi-asserted-by":"publisher","unstructured":"Rojas-Marcos I. Muscular dystrophies. Med 2019; 12. https:\/\/doi.org\/10.1016\/j.med.2019.04.003.","DOI":"10.1016\/j.med.2019.04.003"},{"key":"5166_CR65","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fcell.2014.00011","volume":"2","author":"Y Ogura","year":"2014","unstructured":"Ogura Y, Tajrishi MM, Sato S, Hindi SM, Kumar A. Therapeutic potential of matrix metalloproteinases in Duchenne muscular dystrophy. Front cell Dev Biol. 2014;2:11.","journal-title":"Front cell Dev Biol"},{"key":"5166_CR66","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/mt.2010.261","volume":"19","author":"A Malerba","year":"2011","unstructured":"Malerba A, Sharp PS, Graham IR, Arechavala-Gomeza V, Foster K, Muntoni F, et al. Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice. Mol Ther. 2011;19:345\u201354.","journal-title":"Mol Ther"},{"key":"5166_CR67","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1073\/pnas.0508917103","volume":"103","author":"MA Denti","year":"2006","unstructured":"Denti MA, Rosa A, D\u2019Antona G, Sthandier O, De Angelis FG, Nicoletti C, et al. Body-wide gene therapy of Duchenne muscular dystrophy in the mdx mouse model. Proc Natl Acad Sci USA. 2006;103:3758\u201363.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5166_CR68","doi-asserted-by":"crossref","unstructured":"Niks EH, Aartsma-Rus A. Exon skipping: a first in class strategy for Duchenne muscular dystrophy. 101080\/1471259820171271872 2016; 17: 225\u201336.","DOI":"10.1080\/14712598.2017.1271872"},{"key":"5166_CR69","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1038\/nm.3990","volume":"21","author":"NA Dumont","year":"2015","unstructured":"Dumont NA, Wang YX, Von Maltzahn J, Pasut A, Bentzinger CF, Brun CE, et al. Dystrophin expression in muscle stem cells regulates their polarity and asymmetric division. Nat Med. 2015;21:1455\u201363.","journal-title":"Nat Med"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05166-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05166-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05166-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T06:04:56Z","timestamp":1662703496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05166-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,9]]},"references-count":69,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["5166"],"URL":"https:\/\/doi.org\/10.1038\/s41419-022-05166-0","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,9]]},"assertion":[{"value":"10 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"779"}}